A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Saluda Medical Announces $125M Equity Financing

Led by Redmile Group LLC and New Investors Fidelity Management & Research Company LLC and T. Rowe Price Associates, Inc.

Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile Group LLC as well as new investors Fidelity Management & Research Company LLC, and funds and accounts advised by T. Rowe Price Associates, Inc.

Saluda Medical advises the net proceeds from the financing will be used to operationalize and scale commercialization of the Evoke® Spinal Cord Simulation System (SCS) for chronic pain and to further advance the Company’s technology platform across an emerging portfolio of transformational neuromodulation therapies.

Evoke® is the only spinal cord stimulation technology designed to measure the spinal cord’s response to stimulation and make automatic, real-time adjustments intended to maintain a consistent level of pain therapy.

“We are thrilled to partner with this group of leading healthcare investors who share our vision of elevating the standard of care in neuromodulation fields with large unmet patient needs,” said Jim Schuermann, President and CEO of Saluda Medical. “The full impact of our innovation can only be realized by enabling more patients to be treated with our evidence-based technologies designed to improve long-term outcomes while reducing the burden of care, and we wish to thank our new and existing investors for their partnership in our journey to achieve this mission.”

Saluda Medical has pioneered innovations designed to read, record, and respond to nerves during stimulation and over the last decade has advanced the technology to enable dosing that can be titrated at the microsecond level to maintain and optimize consistent therapy for patients. The Company executed the first double-blind pivotal randomized controlled trial (RCT) in the history of spinal cord stimulation (SCS) that showed nearly 9 out 10 patients experience long-term pain relief and clinically meaningful improvements in quality of life, performing activities of daily living, sleep, mood and opioid reduction with zero explants due to loss of efficacy. Evoke is the only spinal cord stimulation therapy to have the pivotal study results published in premier clinical neurology journals The Lancet Neurology and JAMA Neurology.

Chronic pain affects more than 540 million people globally. Although spinal cord stimulation has been used as a treatment option for chronic pain since 1967, Evoke is the first system designed to automatically self-adjust with microsecond precision to optimize therapy based on a patient’s unique spinal cord activity.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy